CLX enters its August 3 earnings print with the most negative analyst backdrop it has faced in months — and a short book that barely budged despite the stock holding flat on the week.
The week's defining moment came from Jefferies, which downgraded CLX to Hold from Buy on July 28 and slashed its target from $125 to $98. That is a $27 cut from a firm that was, until days ago, one of the lone bulls on the name. It was the most consequential single analyst move in the pre-earnings window, and it shifted an already-cautious consensus further toward neutral. The rest of the Street has been moving in the same direction: Evercore trimmed to $98 from $110 while keeping its Underperform rating; JP Morgan cut to $92 from $95 while staying Underweight; BNP Paribas eased to $95. Only UBS and Barclays provided any mechanical offset, nudging targets marginally higher — both from Neutral or Underweight stances. The result is a consensus of one Buy against fourteen Holds, a mean target of $102.35, and a price of $95.53. That implied 7% upside sounds reasonable in isolation, but given the direction of travel on estimates, the Street is not exactly queuing to add.
Short positioning remains the other weight on the stock. Bears hold 9.8% of the free float — a level that has climbed roughly 23% over the past month and shows no sign of unwinding ahead of the print. Days to cover runs nearly five, so the short book is not light. The borrow market, however, continues to offer no friction to new shorts. Availability is ample at 280%, meaning roughly three shares sit available to borrow for every one currently on loan. Cost to borrow has actually eased over the week, now at 0.46% — essentially zero carry for bears. Nothing in the lending market discourages the short side from holding through earnings.
Options traders have grown incrementally more defensive, though not dramatically so. The put/call ratio closed Friday at 0.80, above its 20-day average of 0.71 by just over one standard deviation. That is a meaningful drift from mid-July levels near 0.62, and the move has been directional — the ratio has climbed steadily over the past two weeks. It has not yet approached the 52-week high of 0.94, so options do not yet signal acute fear, but the pattern is consistent with cautious hedging building into the release.
The one notable counterpoint in the data is an independent director's open-market purchase in May: Pierre Breber bought 5,000 shares at $85.82, a $429,000 commitment at a price well below where the stock trades today. That is the only meaningful buy signal in the insider record over the past year, and it came at a lower price. Against that, routine executive sells continued through July, though all at low significance scores.
The April earnings print serves as the most relevant recent reference. CLX dropped 8.1% the day after that report and had given back 2.8% by the end of the following week. The stock has barely moved on the week heading into August 3, leaving the setup to turn on whether the company can provide any relief on the volume or margin outlook — two areas where analyst downgrades have concentrated.
See the live data behind this article on ORTEX.
Open CLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
